Shiba Inu burns keep rising but utility remains weak. Analysts say Remittix could deliver far bigger upside this cycle with real payment use cases and momentum.Shiba Inu burns keep rising but utility remains weak. Analysts say Remittix could deliver far bigger upside this cycle with real payment use cases and momentum.

Shiba Inu Coin’s Burn Mechanism Isn’t Enough – Experts Say Remittix’s Utility Could Deliver 100x Instead

Shiba Inu Main2

The meme-coin frenzy around Shiba Inu coin (SHIB Price) has been loud, bold and driven by community hype. Yet now, many analysts say the burn strategy simply won’t cut it for lasting gains. They argue that only a DeFi project with proven utility and real-world traction can bring the ‘next 100× crypto’ effect. Remittix is being touted as the best crypto to buy now, a low gas fee project, and possibly the next big altcoin in 2025 with actual utility compared to SHIB’s speculative show. Investors who want to avoid the regret of missing ‘the next 100×’ are now looking beyond the meme coins.

Remittix

Shiba Inu’s Burn Hype Versus Reality

The Shiba Inu coin (SHIB Price) has recently shown dramatic increases in token burns. Data shows nearly 30 million SHIB tokens were destroyed in 24 hours. The circulating supply is still huge and while the burn rate spike creates buzz, it may not materially tighten supply. 

The community calls it a win; analysts call it too little, too late. While SHIB Price trades in the $0.00001-$0.000013 range and the network activity of its layer-2 solution Shibarium is improving, the underlying supply dynamics and lack of killer utility remain concerns. 

Many investors are saying: being part of SHIB now may still deliver gains, but the odds of massive gains appear lower compared to projects built with real utility. Some industry voices even argue that SHIB’s burn mechanism is not enough to shift the game. If you’re hunting for the “top altcoins to invest in” rather than the next meme wave, you may want to look elsewhere.

Remittix: Real-World Utility Meets Big-Picture Ambition

Remittix

Remittix enters the stage with more than just buzz — it’s a cross-chain DeFi project built for real payments, designed for real people. The platform allows crypto users to send assets directly into bank accounts across 30+ countries, convert into 30+ fiat currencies, and bypass traditional remittance hurdles. 

Compared to SHIB’s meme origins, Remittix offers cold-hard metrics: raised over $27.9 million+ in presale, audited by the top-tier firm CertiK, ranked #1 on its Pre-Launch Token list, and gearing up for listings on major centralized exchanges. Analysts are already calling it “XRP 2.0” given its remittance focus and payment-industry ambitions.

Why Remittix Is Gaining Traction

  • Global reach with crypto-to-bank transfers in 30+ countries.
  • Real-world utility: built for global payments, not just speculation.
  • Security first: audited and verified by CertiK, bringing trust.
  • Wallet coming: mobile-first experience with real-time FX conversion.
  • Strong funding: over $27.9 million raised, showing serious investor backing.
  • Deflationary token model + early-holder benefits, layering upside for early entries.

In a market now favouring early stage crypto investment, Remittix ticks a lot of boxes. If you’re hunting for the next big altcoin in 2025, this may be the one – but only if you act before listings flood and valuations run ahead.

Don’t Settle for Meme Hype When Real Utility Calls

The Remittix team has just launched a new referral programme where every time you refer a buyer, you get 15% of their purchase in USDT — claimable every 24 hours.

With $250,000 in community giveaways already announced, and the wallet beta right around the corner, you’re not just buying a token. Miss it now, and you might regret watching someone else ride the wave. Move while the opportunity is live.

Remittix offers the kind of product, funding, security and timing that may put it in the conversation for a serious breakout. If you’re looking for the best crypto to buy now, not just a gamble, you may want to get involved before the crowd notices.

Discover the future of PayFi with Remittix by checking out their project here:

Website: https://remittix.io/   

Socials: https://linktr.ee/remittix   

$250,000 Giveaway: https://gleam.io/competitions/nz84L-250000-remittix-giveaway

Market Opportunity
BitShiba Logo
BitShiba Price(SHIBA)
$0.0000000004515
$0.0000000004515$0.0000000004515
-0.08%
USD
BitShiba (SHIBA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23